Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.

Age should not be a limiting factor in considering the modality of AHCT. However, younger patients might also benefit from additional novel treatment approaches in the setting of clinical trials, given their similar outcomes with the older patients in our study.